Secukinumab Global MAP Cohort for Adult Patients With Hidradenitis Suppurativa (HS)

Condition:   Hidradenitis Suppurativa (HS) Intervention:   Drug: secukinumab Sponsor:   Novartis Pharmaceuticals Temporarily not available

Source: ClinicalTrials.gov - October 18, 2022 Category: Research Source Type: clinical trials